publication date: Oct. 4, 2017

NCI CTEP-Approved Trials for July

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

 

Phase II     10021
A Phase II Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC

Dana-Farber – Harvard Cancer Center LAO
Schoenfeld, Jonathan Daniel
(617) 632-5734

 

Phase II     10042
A Phase II Trial of AZD9291 (Osimertinib) with or without Bevacizumab in Patients with EGFR Mutation Positive NSCLC and Brain Metastases

Yale University Cancer Center LAO
Goldberg, Sarah B.
(203) 785-7564

 

Phase III     NRG-BN003
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

NRG Oncology
Rogers, C. Leland
(801) 359-8956 X 102

 

Phase Other     AALL17B4-Q
Epigenetic Landscape of Relapsed Pediatric Acute Lymphoblastic Leukemia

Children’s Oncology Group
Carroll, William L.
(212) 263-9947

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.